Welcome

The Michigan Society of Hematology and Oncology (MSHO) is a non-profit 501c(6) corporation, formed in 1985 to address the growing needs of oncologists, radiation oncologists and hematologists in all practice settings in the state.

It is the Mission of MSHO to promote exemplary care for patients with cancer and/or blood disorders through advocacy, education and research.

Upcoming Events view all events

←	August 2020					→
S	M	T	W	T	F	S
						1
2	3	4 Multiple Myeloma - New Indication Hosted by Janssen WEBINAR August 4, 2020 6:00-7:00PM XPOVIO® (selinexor) The first and only FDA-approved oral selective nuclear export inhibitor in relapsed refractory multiple myeloma (RRMM) Hosted by Karyopharm WEBINAR August 4, 2020 12:00-1:00PM	5	6 Oncology Pharmacist Lunch & Lecture Series New Drug Updates: IV Therapies WEBINAR August 6, 2020 12:00-1:00PM	7	8 ASCO20 Virtual Education Program August 8-10, 2020
9 ASCO20 Virtual Education Program August 8-10, 2020	10 ASCO20 Virtual Education Program August 8-10, 2020	11 Survivorship Virtual Speaker Event with Dr. Jennifer Klemp Hosted by AstraZeneca WEBINAR August 11, 2020 6:30-8:00PM	12	13 A Program on An Overview of Multicentric Castleman Disease and Current Treatment Options Hosted by EUSA Pharma WEBINAR August 13, 2020 6:00-7:00PM National Broadcast to Announce the Approval of a Second Indication for TAZVERIK™ (tazemetostat) Hosted by Epizyme WEBINAR - Multiple Broadcast Times August 13-19, 2020 Chemotherapy Safe Handling During COVID-19 Webinar Hosted by ASCO's Clinical Affairs Department August 13, 2020 4:00-5:00PM	14 National Broadcast to Announce the Approval of a Second Indication for TAZVERIK™ (tazemetostat) Hosted by Epizyme WEBINAR - Multiple Broadcast Times August 13-19, 2020	15 National Broadcast to Announce the Approval of a Second Indication for TAZVERIK™ (tazemetostat) Hosted by Epizyme WEBINAR - Multiple Broadcast Times August 13-19, 2020
16 National Broadcast to Announce the Approval of a Second Indication for TAZVERIK™ (tazemetostat) Hosted by Epizyme WEBINAR - Multiple Broadcast Times August 13-19, 2020	17 National Broadcast to Announce the Approval of a Second Indication for TAZVERIK™ (tazemetostat) Hosted by Epizyme WEBINAR - Multiple Broadcast Times August 13-19, 2020	18 Patients With High‐Risk mCRPC Require an Individualized Treatment Approach Hosted by Sanofi Genzyme WEBINAR August 18, 2020 7:00-8:00PM National Broadcast to Announce the Approval of a Second Indication for TAZVERIK™ (tazemetostat) Hosted by Epizyme WEBINAR - Multiple Broadcast Times August 13-19, 2020	19 Virtual Sanofi Genzyme Speaker Event Hosted by Sanofi Genzyme WEBINAR August 19, 2020 7:00-8:00PM Current Challenges in Chemotherapy Induced Nausea and Vomiting Hosted by Heron Therapeutics WEBINAR August 19, 2020 6:30-7:30PM Hematology and Oncology Board Review and Re-Certification Evening Lecture Series Breast Cancer & Hereditary Cancers WEBINAR August 19, 2020 5:15-7:30PM National Broadcast to Announce the Approval of a Second Indication for TAZVERIK™ (tazemetostat) Hosted by Epizyme WEBINAR - Multiple Broadcast Times August 13-19, 2020	20 Oncology Pharmacist Lunch & Lecture Series New Drug Updates: Oral Oncolytics WEBINAR August 20, 2020 12:00-1:00PM	21	22
23	24	25 Operational Efficiencies & Readiness for Value-Based Care WEBINAR August 25, 2020 12:00-1:00PM	26 Hematology and Oncology Board Review and Re-Certification Evening Lecture Series GU Malignancies & Lymphoma/Myeloma WEBINAR August 26, 2020 5:15-7:30PM	27 ASH Meeting on Hematologic Malignancies - A Virtual Experience August 27 - September 12, 2020	28 ASH Meeting on Hematologic Malignancies - A Virtual Experience August 27 - September 12, 2020	29 ASH Meeting on Hematologic Malignancies - A Virtual Experience August 27 - September 12, 2020
30 ASH Meeting on Hematologic Malignancies - A Virtual Experience August 27 - September 12, 2020	31 ASH Meeting on Hematologic Malignancies - A Virtual Experience August 27 - September 12, 2020